Navigation Links
Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models
Date:2/9/2012

WALTHAM, Mass., Feb. 9, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that scientists at Roswell Park Cancer Institute have demonstrated that entinostat, Syndax's novel, oral small molecule inhibitor of class I histone deacetylases, has novel immunomodulatory properties that contribute to the enhanced activity of cancer immunotherapies in models of renal and prostate cancer.  The results were published in PLoS ONE in an article titled, "Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal  and Prostate Cancer Models."

"The results demonstrate a novel immunomodulatory effect of entinostat and provide a rationale for the clinical testing of entinostat to enhance cancer immunotherapy,"  said Roberto Pili, MD, professor of oncology, chief, genitourinary section and co-leader, genitourinary program, department of medicine, Roswell Park Cancer Institute.  "We are interested in testing whether entinostat could improve the benefit seen with immunotherapies in the advanced disease population where oncology treatments are limited."

The results, published in the January 23rd issue of PLOS, show that entinostat inhibits the function of T regulatory cells that are involved in suppressing the anti-tumor activity of immune based therapies. Importantly entinostat maintained the activity of the T effector cell population.

"This exciting pre-clinical data provides new information about entinostat's mechanism of action, expanding the potential for entinostat in new combinations in solid tumors," said Joanna Horobin, MD, president and chief executive officer of Syndax.  "Because of collaborations like this one with the Roswell Park Cancer Institute, we are able to continue to investigate
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat
2. Survival Benefit With Syndax Pharmaceuticals Entinostat Maintained in Women with Advanced Breast Cancer
3. Multiple Data Presentations on Syndax Pharmaceuticals Entinostat at Upcoming Scientific Conferences
4. Pharmacodynamic Data from Syndax Pharmaceuticals ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
5. Syndax Pharmaceuticals to Present at Upcoming Fall Financial Conferences
6. Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference
7. Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
8. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
11. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... N.J. , July 28, 2014   ... $520,000 settlement of off-label marketing and fraud claims ... and Vascular Solutions, Inc. ("VSI").  The settlement covers ... medical devices for endovenous laser ablation of varicose ... Magnanini, a firm with a history of representing ...
(Date:7/28/2014)... -- June 28 th , 2014 – Oncolab, the ... cancer test, is making its AACC debut (booth #4051) at ... is a serum-based in vitro immunoassay, has been run for ... in the fight against cancer recurrence. Photo - ... million cancer survivors in the US alone, the race is ...
(Date:7/28/2014)... 2014 Reportlinker.com announces that a new ... Portugal Pharmaceuticals and Healthcare Report ... Includes 3 FREE quarterly ... growth last quarter has led us to revise ... forecast previously, BMI expects Portugal,s ...
Breaking Medicine Technology:Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 2Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 3Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4
... Prostate Conditions Education Council (PCEC) – a ... in prostate cancer screening – today announced it strongly ... Services Task Force (USPSTF). The draft guidance recommends against ... PCEC believes that until a more accurate and ...
... 10, 2011 PDI, Inc. (Nasdaq: ... R. Melillo, Jr. as senior vice president of Business ... drive PDI,s commercial outsource services and contract sales business. ... officer. Melillo was most recently general manager ...
Cached Medicine Technology:Prostate Conditions Education Council Opposes U.S. Preventative Services Task Force Recommendation 2Prostate Conditions Education Council Opposes U.S. Preventative Services Task Force Recommendation 3PDI Appoints Gerald R. Melillo, Jr. As SVP of Business Development 2
(Date:7/28/2014)... that they monopolize large amounts of sugar. More recently, ... characterized by a series of features such as mobility ... are calling this behavior "mesenchymal," and they suspect it ... was able to demonstrate that the two observations ... the same mechanism, at least in "non-small cell lung ...
(Date:7/28/2014)... 29, 2014 The “Tissue ... Hybridization, Digital pathology & Workflow, Special Staining), ... Cancer, Non Small Cell Lung Cancer and ... Pharmaceutical companies, Research Laboratories, Contract Research Organizations ... Europe, BRIC, Japan & RoW) - Trends ...
(Date:7/28/2014)... TX (PRWEB) July 28, 2014 A lush ... family playtime during the summer. However, the summer heat, lack ... lawn to become brown, weak and unhealthy. The Grounds Guys ... It Grow, Mow a lawn once a week and set ... than normal. This protects the grass roots from heat and ...
(Date:7/28/2014)... UHY LLP, a member of the ... UHY International Business – Issue 29. This bi-annual publication ... most current business challenges and key issues faced by ... the following topics:, , Key industry ... over the next five years? Where are growth opportunities ...
(Date:7/28/2014)... 2014 Dawn Echols’ professional background ... and music. This experience has honed her people ... psychology. Her professional counseling ( http://dawningphoenix.com ) work ... for offenders in domestic violence. , As ... she enjoys counseling individuals and groups for a ...
Breaking Medicine News(10 mins):Health News:Cancer: Tumors absorb sugar for mobility 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2
... Perot Systems,Corporation (NYSE: PER ) ... received the #1 ranking in the KLAS ... implementation services(1). Known throughout,the Healthcare industry for ... informed technology decisions by independently,monitoring vendor performance ...
... LA JOLLA, CA Diabetic individuals have a ... the molecular connection between the two remains unexplained. ... Studies identified the probable molecular basis for the ... published in the current online issue of Neurobiology ...
... How Drugs Actually Work in Real ... ... free,patient-driven online healthcare community, announced the launch of an,innovative new tool that ... taking prescription drugs, and eight out of,ten surfing the web for their ...
... Hillenbrand, Inc.,(NYSE: HI ) today announced that ... a publicly traded company of $0.1825 per share,on the ... 2008 to,shareholders of record at the close of business ... board to approve this inaugural dividend is based,on the ...
... Pet Week, May,4-10, celebrates the relationships formed between ... emphasize the caretaking actions we can take for ... recommended by,your veterinarian; giving them plenty of attention, ... pets safe and pleasant., "Being a responsible ...
... Tex. April 30, 2008 - Despite the general ... critically ill heart failure patients, implantation of these devices ... high-volume blood transfusions during and immediately after surgery. A ... that the incidence of these complications may be significantly ...
Cached Medicine News:Health News:Perot Systems Ranked #1 for Clinical Implementation Services By KLAS 2Health News:Perot Systems Ranked #1 for Clinical Implementation Services By KLAS 3Health News:Salk study links diabetes and Alzheimer's disease 2Health News:Salk study links diabetes and Alzheimer's disease 3Health News:iGuard.org Alters the Face of E-Health: New Web Service Draws 10,000 New Patients Weekly 2Health News:iGuard.org Alters the Face of E-Health: New Web Service Draws 10,000 New Patients Weekly 3Health News:Hillenbrand, Inc. Declares First Quarterly Dividend As a New Publicly Traded Company 2Health News:California Veterinarians Recognize National Pet Week With Tips to Keep Your Animal in a Safe Environment 2Health News:California Veterinarians Recognize National Pet Week With Tips to Keep Your Animal in a Safe Environment 3
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... nm and 940 nm) laser system is ... solid-state laser quickly and effectively treats vascular ... offers the clinical versatility to precisely target ... vessels in a convenient, affordable package. , ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
Medicine Products: